Epuration extra rénale : ce qu'il faut retenir - JLAR

7. Schiffl H, Lang SM, Konig A, Strasser T, Haider MC, Held E. Biocompatible membranes in
acute renal failure: prospective case-controlled study. Lancet 1994;334:570-572.
8. Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of
patients with acute renal failure. N Engl J Med 1994;331:1338-1342.
9. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Removal of proinflammatory
cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med
1995;21:169-176.
10. Canaud B, Leblanc M, Delmas S, Leray-Moragues H. Epuration extra-rénale continue en
réanimation. Accès vasculaires, sites et biomatériaux. Réan Urg 1998;7:207-214.
11. Journois D, Chanu D, Pouard P, Mauriat P, Safran D. Assessment of standardized
ultrafiltrate production rate using prostacyclin in continuous venovenous hemofiltration. In:
Sieberth HG, Mann H and Stummvoll HK, editors. Continuous hemofiltration. Basel: Karger; 1990.
p. 202-204.
12. Hory B, Cachoux A, Toulemonde F. Continuous arteriovenous hemofiltration with lowmolecular-weight
heparin (letter). Nephron 1985;41:125.
13. Mehta R, McDonald B, Aguilar M, Ward D. Regional citrate anticoagulation for continuous
arteriovenous hemodialysis in critically ill patients. Kidney Int 1990;38:976-981.
14. Journois D, Safran D, Castelain M, Chanu D, Drevillon C, Barrier G. Comparaison des
effets antithrombotiques de l’héparine, l’énoxaparine et de la prostacycline au cours de
l’hémofiltration continue. Ann Fr Anesth Réanim 1990;9:331-337.
15. Bellomo R, Martin H, Parkin G, Love J, Kearley Y, Boyce N. Continuous arteriovenous
haemodiafiltration in the critically ill: influence on major nutrient balances. Intensive Care Med
1991;17:399-402.
16. Schetz M. Drug removal with continuous renal replacement therapies. In: Journois D, editor.
Continuous hemofiltration in the intensive care unit. Amsterdam: OPA; 1997. p. 69-77.
17. Golper TA, Pulliam J, Bennett WM. Removal of therapeutic drugs by continuous
arteriovenous hemofiltration. Arch Intern Med 1985;145:1651-2.
18. Hoffmann JN, Werdan K, Hartl WH, Jochum M, Faist E, Inthorn D. Hemofiltrate from
patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic
compounds. Shock 1999;12:174-80.
19. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs.
convective therapy: effects on mediators of inflammation in patient with severe systemic
inflammatory response syndrome. Crit Care Med 1998;26:1995-2000.
20. Wang W, Huang HM, Zhu DM, Chen H, Su ZK, Ding WX. Modified ultrafiltration in
paediatric cardiopulmonary bypass. Perfusion 1998;13:304-10.
21. Journois D, Israel-Biet D, Pouard P, Rolland B, Silvester W, Vouhe P, et al. High-volume,
zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass
in children. Anesthesiology 1996;85:965-76.
22. Veenman JN, Dujardint CL, Hoek A, Grootendorst A, Klein WR, Rutten VP. High volume
continuous venovenous haemofiltration (HV-CVVH) in an equine endotoxaemic shock model.
Equine Vet J 2002;34:516-22.
23. Eising GP, Schad H, Heimisch W, Gippner-Steppert C, Jochum M, Braun SL, et al. Effect
of cardiopulmonary bypass and hemofiltration on plasma cytokines and protein leakage in pigs.
Thorac Cardiovasc Surg 2000;48:86-92.
24. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume
haemofiltration in human septic shock. Intensive Care Med 2001;27:978-86.
25. Schetz M. Non-renal indications for continuous renal replacement therapy. Kidney Int Suppl
1999;72:S88-94.
26. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, et al. A phase II
randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
JLAR 2007